Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

Fungicide sales were up 0.5% as volume recovery slightly outweighed a decline in prices ... that Bayer’s HealthCare unit co-develops Eylea with Regeneron REGN, which records net product ...

Regeneron reported Eylea sales of $4.7 billion in the first six months of the year - a decline of 4%, with $2.9 billion from that total coming from the US market. Sales of Vabysmo, meanwhile ...

Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks ...

Analysts are intrested in these 5 stocks: ( ($MRK) ), ( ($REGN) ), ( ($CLRB) ), ( ($HUMA) ) and ( ($FL) ). Here is a ...

The MERLIN study was comparing Beovu to Eylea ... drug's sales momentum if approved. Filings are due before the end of the year. Bayer's CEO says new product launches will offset the decline ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion in ...

Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Regeneron Pharmaceuticals said Monday it will buy genetic testing company 23andMe out of bankruptcy for $256 million, a deal ...

Since recreational cannabis was legalized in Illinois starting in 2020, sales of the drug have increased to $2 billion a year. The holiday this year has morphed into a weekendlong cultural ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.